Autologous CAR-T cell manufacturing takes up to a month and costs half a million dollars per patient. Multiplex base editing knocks out TCR and HLA Class I in healthy donor T-cells without double-straβ¦
π§ͺ Multiplex Genomic Engineering: Clean base editing knocks out TRAC and B2M with 97.4% efficiency without creating double-strand DNA fractures.
π₯ Same-Day Cryobank Infusion: Pre-manufactured donor cohorts achieved an 88% complete remission rate in refractory B-ALL cohorts without graft-versus-host complications.
Editing Method: Multiplex Base Editing (CBE)
Target Loci: TRAC, B2M, CD52
Knockout Efficiency: 97.4%
Storage: Cryopreserved LN2 (-196Β°C)
Autologous CAR-T cell manufacturing takes up to a month and costs half a million dollars per patient. Multiplex base editing knocks out TCR and HLA Class I in healthy donor T-cells without double-strand DNA breaks, generating an off-the-shelf universal cryopreserved cell product ready for same-day infusion.
Enables immediate cellular immunotherapy delivery for aggressive refractory acute lymphoblastic leukemia.
Regulatory frameworks and infrastructure readiness remain critical.
Standardized allogeneic cryobanks will replace individualized autologous manufacturing by 2029.